Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Louisiana for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Louisiana only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Louisiana (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jack Saux (NPI 1528023843)

Field	Value
Entity Type	Individual
Organization	Jack Saux
Address	1203 S Tyler St Ste 230
City	Covington
State	LA
ZIP	70433
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 19, 2006

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is concentrated in high-cost oncology biologics: J9299 (nivolumab) and J9271 (pembrolizumab) together account for a large share of drug revenue, and the precomputed top-3 codes by revenue account for 78.0% of this provider's total Medicare revenue. J9299 alone represents $1.2M (42.6% of Medicare revenue) and J9271 contributes $782.9K (27.6%), indicating the clinical operation is heavily weighted toward checkpoint inhibitor administration rather than a broad mix of outpatient services.

JACK SAUX is effectively single‑payer from a claims perspective: reported lifetime Medicare revenue is $2.8M while there is no Medicaid billing on file. This absence of Medicaid activity means payer risk and revenue exposure are concentrated in the Medicare population and any Medicare policy or reimbursement changes for infused oncology drugs would disproportionately affect the practice.

J9299 is a national outlier for volume: the provider ranks #11 of 505 nationally for J9299 (98th percentile; notably above typical national volume for this code). That high rank for nivolumab suggests the provider is a major regional or specialty source for this specific immunotherapy relative to peers, while the companion immunotherapy J9271 ranks more modestly at #492 of 1841 (73rd percentile; typical, unremarkable volume for this code).

Although drug administration dominates revenue, E/M activity for complex established visits is unusually high relative to peers: 99215 produced $193.8K (6.8% of Medicare revenue) with 1.5K claims and ranks #68 of 145531 providers nationally (100th percentile; extreme outlier). This pattern—both high-volume high-level E/M coding and intensive biologic infusion—points to a practice managing many complex, ongoing oncology patients rather than sporadic consults.

Beyond the top immunotherapy codes, the provider shows elevated administration and infusion service volumes on several chemotherapy and infusion-related codes. For example, 96413 ($59.9K, 2.1% of Medicare revenue) ranks #305 of 7514 (96th percentile; notably above typical national volume for this code) and 96372 ($6.2K, 0.2% of Medicare revenue) ranks #1096 of 58224 (98th percentile; notably above typical national volume for this code), reinforcing that the operation performs frequent infusion procedures in addition to dispensing specialty biologics.

Revenue concentration creates commercial sensitivity: with the top three codes making up 78.0% of Medicare revenue and J9299 alone at $1.2M (42.6%), the practice’s financial performance is highly dependent on continued utilization and reimbursement of a small set of high-cost agents. Any formulary, prior authorization, or reimbursement changes affecting nivolumab, pembrolizumab, or the listed immunoglobulin product could materially shift billing and revenue patterns for this provider.

Provider tenure is long-standing: the NPI was enumerated 2006-04-19 (~20 years ago), indicating sustained participation in Medicare over two decades. That longevity, combined with extreme and notably above-typical volume ranks on several codes, suggests an established oncology practice with stable referral and treatment patterns in its market.

Competitive standing is mixed by code: the provider is a dominant national-level performer for J9299 (98th percentile) and an extreme outlier on 99215 (100th percentile), but for many other oncology and infusion codes the provider’s ranks fall in typical or moderately elevated percentiles (for example, J1568 at #61 of 381, 84th percentile; J9271 at 73rd percentile). This profile indicates specialty dominance in select high-value drugs alongside otherwise conventional participation in chemotherapy administration and supportive-care services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

38 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	50,390	$20	$1.2M
J9271	Injection, pembrolizumab, 1 mg	18,210	$40	$782.9K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	6,500	$30	$221.1K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	1,510	$130	$193.8K
J0897	Injection, denosumab, 1 mg	5,580	$20	$106K
J1437	Injection, ferric derisomaltose, 10 mg	4,100	$20	$69.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	670	$90	$59.9K
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	6,860	$10	$41.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	460	$80	$38.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	400	$80	$32.9K

Showing 1–10 of 38

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 38 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Louisiana Distribution

Jack Saux — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Louisiana

Full comparison — all codes billed, vs. state median

38 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9299	1	10	39,670	$20	$929.9K
J9271	2	10	13,800	$40	$635.1K
J1568	1	10	6,500	$30	$218.7K
J0897	25	70	3,120	$20	$105.6K
J3490	11	20	50	$620	$49.1K
J1437	2	10	1,900	$20	$41.9K
J2506	3	10	400	$80	$38.2K
96413	6	70	140	$90	$22.8K
99214	834	6,670	110	$80	$16.5K
Q0138	5	10	23,720	$1	$13.4K

Showing 1–10 of 38

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jack Saux, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Capitol City Family Health Center Incorporated	LA	Federally Qualified Health Center (FQHC)	$0	$21.6M
Mary Bird Perkins Cancer Center	LA	Clinical Medical Laboratory	$64.4K	$8.4M
Barry Charnick	FL	Nuclear Radiology Physician	$1.3M	$0
Daniel Lavie	LA	Hematology & Oncology Physician	$1.1M	$0
Bryan Bienvenu	LA	Hematology & Oncology Physician	$964.2K	$0
Manish Dhawan	LA	Hematology & Oncology Physician	$870.9K	$24.3K
Jingya Wang	LA	Radiation Oncology Physician	$856.4K	$0
Andrew Elson	LA	Radiation Oncology Physician	$825.1K	$0
Gregory Henkelmann	LA	Radiation Oncology Physician	$754.9K	$0
Konstantin Kovtun	LA	Radiation Oncology Physician	$709K	$0

Nearby Providers

Other providers in the same ZIP code as Jack Saux, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
St. Tammany Parish Hospital Service District No 1	LA	General Acute Care Hospital	$0	$16.5M
Regional Radiology, LLC	LA	Diagnostic Radiology Physician	$0	$15.6M
Avenues Recovery Center At Covington	LA	Substance Abuse Rehabilitation Facility	$0	$15.4M
Right Hand Senior Care LLC	LA	In Home Supportive Care Agency	$0	$13.5M
Easter Seals Louisiana Inc.	LA	Case Management Agency	$0	$11.4M
Pontchartrain Pediatrics LLC	LA	Pediatrics Physician	$0	$11.3M
Townsend Recovery Center New Orleans, LLC	LA	Substance Abuse Rehabilitation Facility	$0	$10.8M
Quality Support Coordination Inc	LA	Case Management Agency	$0	$10M
St Tammany Emergency Physicians Group LLC	LA	Emergency Medicine Physician	$0	$9.2M
Start Corporation	LA	Federally Qualified Health Center (FQHC)	$0	$7.5M

Jack Saux — Billing Profile & Reimbursement Data

Sign up for Jack Saux — Billing Profile & Reimbursement Data policy alerts

Jack Saux — Billing Profile & Reimbursement Data

Sign up for Jack Saux — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References